Path4Drug: Data Science Workflow for Identification of Tissue-Specific Biological Pathways Modulated by Toxic Drugs

The early prediction of drug adverse effects is of great interest to pharmaceutical research, as toxicity is one of the leading reasons for drug attrition. Understanding the cell signaling and regulatory pathways affected by a drug candidate is crucial to the study of drug toxicity. In this study, we present a computational technique that employs the propagation of drug-protein interactions to connect compounds to biological pathways. Target profiles for drugs were built by retrieving drug target proteins from public repositories such as ChEMBL, DrugBank, IUPHAR, PharmGKB, and TTD. Subsequent enrichment test of the protein pool using Reactome revealed potential pathways affected by the drugs. Furthermore, an optional tissue filter utilizing the Human Protein Atlas was applied to identify tissue-specific pathways. The analysis pipeline was implemented in an open-source KNIME workflow called Path4Drug to allow automated data retrieval and reconstruction for any given drug present in ChEMBL. The pipeline was applied to withdrawn drugs and cardio- and hepatotoxic drugs with black box warnings to identify biochemical pathways they affect and to find pathways that can be potentially connected to the toxic events. To complement this approach, drugs used in cardiac therapy without any record of toxicity were also analyzed. The results provide already known associations as well as a large amount of additional potential connections. Consequently, our approach can link drugs to biological pathways by leveraging big data available in public resources. The developed tool is openly available and modifiable to support other systems biology analyses.

[1]  Fiona M. I. Hunter,et al.  Drug Safety Data Curation and Modeling in ChEMBL: Boxed Warnings and Withdrawn Drugs , 2021, Chemical research in toxicology.

[2]  Farizatul Akmawati Yahya,et al.  A brief overview to systems biology in toxicology: The journey from in to vivo, in-vitro and –omics , 2021, Journal of King Saud University - Science.

[3]  Daniel P. Morin,et al.  Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease , 2020, Journal of cardiovascular electrophysiology.

[4]  Adam J Pawson,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY , 2019, Nucleic Acids Res..

[5]  Feng Zhu,et al.  Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics , 2019, Nucleic Acids Res..

[6]  Thawfeek M. Varusai,et al.  The reactome pathway knowledgebase , 2019, Nucleic Acids Res..

[7]  A. Bleich,et al.  Animal to human translation: a systematic scoping review of reported concordance rates , 2019, Journal of Translational Medicine.

[8]  Ishani Shah,et al.  Mifepristone: An Uncommon Cause of Drug-Induced Liver Injury , 2019, Gastroenterology research.

[9]  Andrew R. Leach,et al.  ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..

[10]  E. Paschetta,et al.  Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution. , 2018, Trends in pharmacological sciences.

[11]  Subha Kalyaanamoorthy,et al.  Development of Safe Drugs: The hERG Challenge , 2018, Medicinal research reviews.

[12]  M. Moreno-Aliaga,et al.  Maresin 1 mitigates liver steatosis in ob/ob and diet-induced obese mice , 2018, International Journal of Obesity.

[13]  Ryan Miller,et al.  WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research , 2017, Nucleic Acids Res..

[14]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[15]  Henning Hermjakob,et al.  The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..

[16]  Maria Jesus Martin,et al.  The Proteins API: accessing key integrated protein and genome information , 2017, Nucleic Acids Res..

[17]  Gary R. Mirams,et al.  Systems Toxicology: Real World Applications and Opportunities , 2017, Chemical research in toxicology.

[18]  Lincoln Stein,et al.  Reactome pathway analysis: a high-performance in-memory approach , 2017, BMC Bioinformatics.

[19]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[20]  K. Tao,et al.  Maresin 1, a Proresolving Lipid Mediator, Mitigates Carbon Tetrachloride-Induced Liver Injury in Mice , 2016, Oxidative medicine and cellular longevity.

[21]  Robert Preissner,et al.  WITHDRAWN—a resource for withdrawn and discontinued drugs , 2015, Nucleic Acids Res..

[22]  Hui Zeng,et al.  Drug-Path: a database for drug-induced pathways , 2015, Database J. Biol. Databases Curation.

[23]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[24]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[25]  Robert Petryszak,et al.  UniChem: a unified chemical structure cross-referencing and identifier tracking system , 2013, Journal of Cheminformatics.

[26]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[27]  Thorsten Meinl,et al.  KNIME - the Konstanz information miner: version 2.0 and beyond , 2009, SKDD.

[28]  A. Yuryev In silico pathway analysis: the final frontier towards completely rational drug design , 2008, Expert opinion on drug discovery.

[29]  B. Ganter,et al.  Emerging applications of network and pathway analysis in drug discovery and development. , 2008, Current opinion in drug discovery & development.

[30]  Division on Earth Toxicity Testing in the 21st Century: A Vision and a Strategy , 2007 .

[31]  J. Kapitulnik Bilirubin: An Endogenous Product of Heme Degradation with Both Cytotoxic and Cytoprotective Properties , 2004, Molecular Pharmacology.

[32]  I. Paakkari,et al.  Cardiotoxicity of new antihistamines and cisapride. , 2001, Toxicology letters.

[33]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[34]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.